



Industry view on the implementation and review of Regulation 1107/2009

Aurélie Dhaussy, ECPA regulatory Affairs Manager

CEUREG Forum XXI, 24-25 October 2017

1. Current situation

2. Active substance evaluations

- a) Endocrine disruption
- b) Article 4.7 and negligible exposure exceptions
- c) Draft Bee Guidance Document
- d) Import tolerances

3. AIR process


- a) Current issues
- b) Classification process for ASs

1. Zonal process

- a) PPP evaluation issues
- b) Article 43

2. Looking for improvements

- a) Review of 1107/2009 & 396/2005
- b) Data call-in system
- c) Guidance document development




Current situation

Current situation of crop protection



Figure 1: The increasing cost of bringing a new Active Ingredient to the market



* Results of a study undertaken for ECPA and CropLife America

Innovation framework

Market introduction


Figure 10: Share of Active Ingredients introduced or in development

Figure 5: Agrochemical Active Ingredients in development




1990 - 1999

Total = 128 Active Ingredients



2005 - 2014

Total = 73 Active Ingredients



■ Europe ■ Rest of world



Authorisation hurdles hinder innovation!

Timelines for new active substances

Period: 2011-2016

Regime	Submission to authorisation Average (m)	New Actives registered with products	Actives pending	Oldest pending active
Australia	33	5	0	NA
Brazil	79	1	4	March-13
Canada	30	4	0	NA
Japan	33	4	1	Mar-12
USA	30	3	0	NA
1107/2009	48	3	6	Jul-11

- 54 new substances submitted since June 2011
- 23 substances have an Approval vote (3 non-approval)
- 8 have products authorised - 4 conventional, 4 low risk

Better reward for innovation in other markets
-EU farmers at competitive disadvantage

Commission report: July 2017




Chart 5 Number of applications received for evaluation (2013&2014) and decisions taken

Commission report: July 2017




Chart 7 Average time for zonal evaluation





Chart 6 Percentage of compliance with legal deadlines (zRMS)



Products: past performance



Graph 4. Average decision time (in months) for decisions on applications 2012/2013



Source: Report by Directorate F: Implementation of the authorisation requirements of Regulation (EC) 1107/2009.

Active substance evaluation

Endocrine Disruptors

ECPA position

- Criteria are not suitable for regulatory decision-making
 - *Limited to WHO/IPCS definition (hazard identification only)*
 - *No hazard characterisation (no potency)*
 - *Amendment to derogation omitted from proposal*
- However, we acknowledge MSs have decided to approve the criteria.
 - Now in the hands of the Parliament and Council...
- *As a next step, the amendment to the derogation must be re-introduced as promised by the Commission*

Article 4.7 & Negligible exposure

Issues/Challenges



- Draft guidance for negligible exposure for human assessment available only, no draft for the environment
 - ***Draft GD is used as a basis for evaluation***
- Art 4(7) protocols for herbicides & insecticides, not fungicides – deficiencies in herbicide protocol identified
 - ***Little experience how to assess & unclear decision making process***
- **Next steps in decision making**
 - Policy discussion with SCoPAFF

Article 4.7 & Negligible exposure

ECPA position

- ▶ **Pragmatic implementation of the guidance on NE**
- ▶ **Approval through NE provision allows maintenance of some key substances in the farmers tool box**
- ▶ **Although Regulation 1107/2009 is hazard based a risk assessment is essential to demonstrate Negligible Human Exposure**
- ▶ **Future legislative proposals, like for Endocrine, should be based on Negligible risk**
-already today for Biocides

EFSA Bee Guidance

- ECPA in dialogue with policy makers since 2012
 - No substantial changes on the document since July 2013
- Majority of Member States continue to oppose the formal adoption of the document (noting procedure)
- Implementation plan still on hold within DG SANTE
 - Commission's "notice" would be enough to set up **an implementation plan** = no vote
 - Commission needs a vote in Standing Committee on **amendment to the Uniform Principles regulation** (trigger values change to be aligned with the GD content)
- Industry proposal of EU bee risk assessment scheme finalised in June 2017 and shared with Commission/MS



EFSA Bee Guidance

Industry proposal for refinement



- **The EFSA document is not practical and cannot be used without major revisions before implementation**
 - In its current form, it is generating a number of uncertainties and data gaps in the conclusions of risk assessments, as observed in nearly all the EFSA journals on active substances published since January 2016
- **The ECPA Proposal summarize the outcome of over 3 years of research to propose refinements to the EFSA Bee Guidance that could be developed further with Member State & EFSA Experts**
 - It includes the outcome of collaboration with expert groups during workshops, as well as experience in method development

Industry is committed to pursue dialog with regulatory authorities and EFSA to share our experience and data to help develop a workable way forward

Import tolerances policy

Issues/Challenges


- ▶ **Hazard criteria will have a significant impact**
 - ▶ On product availability - in EU
 - ▶ On regulatory coherence - globally
 - ▶ **Suggested EU policy on setting Import Tolerances communicated in SCoPAFF-Residues (June 2017)**
 - ▶ Would be incompatible with EU law and WTO rules
 - ▶ Would also impact EU MRL setting and EU production
- ***Continued input at political and trade level need for a workable policy***

Impact on production and trade

(Hazard based policy in setting import tolerances)



European Union 2016 Covered Commodity Imports, Value in Euros



Import tolerances

ECPA Position

■ **ECPA supports approach “a” - to maintain existing (& set new) import tolerances after risk assessment**

➤ *As required under 396/2005!*

■ **Approach “b” would lead to arbitrary set of different approval decisions**

➤ Inconsistent with residues legislation

➤ Incoherence with better regulation

➤ Open to legal challenges in the EU & WTO



AIR process

AIR process

Delays in evaluation of AIR

- Especially AIR-3, but leading to delays for AIR-4, AIR-5...
- *Options to ensure realistic timelines?*
- *Workload concerns for zRMS?*

EFSA role in peer review

- **Conservative conclusions makes decisions difficult**
 - Genotox
 - Classification
 - Etc...
- **PSN discussions on changes in process?**
 - Will this help the process?

Classification in AS evaluation

EFSA suggestions for harmonised classification unhelpful

- Numerous proposals for new classifications
 - *ECHA should lead the classification process!*
- Classification template could help
- Legislative measures needed to improve the process
 - *Draft Regulation to be discussed in October SCoPAFF?*

ECHA classification process has challenges


- Key issues and future options?

Zonal process

zRMS Registrations New Formulations




Time taken for zRMS to process zonal application



Granted Zonal authorisations within 18 months or less = 21%

Pending Zonal evaluations already exceeding 18 months = 62%


cMS Registrations New Formulations



Granted cMS authorisations **within 4 months or less = 10%**

Pending cMS evaluations already **above 4 months = 67%**

Mutual Recognition



■ **Granted MR authorisations**

within 4 months or less = 9%



■ **Pending evaluations already**

above 4 months = 84%

above 8 months = 63%


above 12 months = 43%

Emergency authorisations Art 53



New MRLs (2014-16)

Chart 7.2 New MRLs



**Delays in MRL process further delays
introduction of new innovative products**

Article 43 re-authorisations

Some improvement in Guidance document

- Revised version adopted October 2016

Remaining, main difficulties

- MS to follow GD, diversity of interpretations
- Timelines of zRMS Allocation
- Timing of Category 4 studies decisions: only one submission
- Mixtures: avoid *multiple* dossiers/timelines
- Pending evaluations new products: allow update to new endpoints

Looking for improvement

Review of Regulations 1107/2009 & 396/2005

Commission consultants have now started work

- Stakeholder meetings and surveys in 2017
- Final report expected mid-2018

Other inputs into the debate...

- Scientific Advice Mechanism (SAM) have been requested to provide input by November 2017
- European Parliament report of Reg.1107/2009 evaluation report expected in March 2018 and vote on political report in July 2018.

No date for legislative proposals...

Phase 1: Implement current framework

AS evaluation

- Guidance document development
- EFSA dialogue

Zonal

- Application of Article 43
- Inter-zonal cooperation
- Zonal coordination helpdesk
- Reducing national requirements
- Efficacy evaluation

MRL evaluation

- Application of Article 12
- MRL revision after AS re-approval

Phase 2: Detailed legislative review

AS evaluation

- Re-focus on risk based system
- Consider benefits of crop protection
- Central evaluation (& central fees)
- Unlimited approval period for ASs
- Data call-in system
- Compulsory data access (& 10yr DP)

Zonal

- De-coupling review of ASs & PPPs
- Improvements in zonal concept
- Changes in Article 43

MRL evaluation

- Fast-track MRLs (default MRLs, MU)
- Central evaluation system (on-line)
- Remove scrutiny procedure for MRL

View shared by ECPA-ECCA-IBMA:

- **Data Call-In (DCI) principle** - Introducing a data call-in system in Europe would ensure a more predictable process for the renewal of approvals.
- **Decouple review of ASs & PPPs** - Time needed for applicants and MS authorities to adjust PPP authorisations to changes resulting from the AS renewal.
- **Realistic timelines** - Pragmatic timelines required to improve predictability and allow forward planning by companies, MSs, EFSA and Commission.
- **Definitions, Scope and Incentives** - Definitions and the scope (Article 2) need to be revised (inc. Bio-stimulants, Protected crops...). Incentives for low-risk ASs & PPPs should also be revised.

Data call-in process

Benefits

Learn from US/Canadian system

- Promotes cooperation for single dossier submission
- More predictable process (clarity on data required)
- Resources and workload can be properly balanced
 - Submission linked to **scientific** need - not deadline
 - Removes need for AS approval extensions...
 - Focus on new data and criteria
- Focus on issues and not active substances
 - Better comparison of submissions
 - Equal treatment?

GDs need be 'Fit for Purpose'...

- **Provide predictability and consistency, for:**
 - EU AS evaluations
 - MS/Zonal PPP evaluations
- **Be workable for all evaluators**
 - Focus on need of end-users by involving them!!
 - Clearly agreed protection goals
 - PPR Panel should ensure quality of science
- **Consistent and coherent implementation**

Guidance document development

ECPA view

Involve end users in developing guidance

- Developed by working groups made up of end users
- Taking into account the needs of all users!
- PPR should review quality of science

Testing phase before full implementation

- Allowing feedback and adjustments where necessary

Define realistic implementation timelines, considering:

- Testing capacity
 - Time needed to update risk assessment
- 



Thank you!